

# DBCG

**DANISH BREAST CANCER COOPERATIVE GROUP**

**INFORMATIONSBLAD NR 36**

**JUNI 2004**

---

## **ADDENDUM I**

### **DBCG's publikationsliste**

Reference 1 – 186 se Informationsblad nr. 32, april 2000, addendum II

187. Anderson M, Kamby C, Jensen M-B, Mouridsen H, Ejlertsen B, Dombernowsky P, Rose C, Cold S, Overgaard M, Andersen J and Kjær M on behalf of the Danish Breast Cancer Co-operative Group. *Tamoxifen in High-risk Premenopausal Women with Primary Breast Cancer Receiving Adjuvant Chemotherapy. Report from the Danish Breast Cancer Co-operative Group DBCG 82B Trial*. Eur J Cancer **1999**; 35:1659-1666.
188. Groenvold M, Fayers PM, Sprangers MAG, Bjorner JB, Klee MC, Aaronson NK, Bech P, Mouridsen HT. *Anxiety and Depression in Breast Cancer Patients at Low Risk of Recurrence Compared with the General Population: A Valid Comparison?* J Clin Epidemiol **1999**; 52:523-530.
189. Mortensen K, Holck S, Christensen IJ, Skouv J, Hougaard DM, Blom J, Larsson LI. *Endothelial Cell Nitric Oxide Synthase in Peritumoral Microvessels Is a Favorable Prognostic Indicator in Premenopausal Breast Cancer Patients*. Clin Cancer Res **1999**; 5:1093-1097.
190. Overgaard M, Jensen M-B, Overgaard J, Hansen PS, Rose C, Andersson M, Kamby C, Kjær M, Gadeberg CC, Rasmussen BB, Blichert-Toft M, Mouridsen HT. *Postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial*. Lancet **1999**. 353:1641-1648.
191. van Tienhoven G, Voogd AC, Peterse JL, Nielsen M, Andersen KW, Mignolet F, Sylvester R, Fentimann IS, van der Schueren E, van Zijl K, Blichert-Toft M, Bartelink H, van Dongen JA on behalf of the EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group. *Prognosis after Treatment for Loco-regional Recurrence after Mastectomy or Breast Conserving Therapy in Two Randomized Trials (EORTC 10801 and DBCG-82TM)*. Eur J Cancer **1999**; 35:32-38.
192. Wohlfahrt J, Andersen PK, Mouridsen HT, Adami HO, Melbye M. *Reproductive History and Stage of Breast Cancer*. Am j Epidemiol **1999**; 150:1325-30.
193. Højris I, Overgaard M, Christensen JJ, Overgaard J. *Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials*. Lancet **1999**; 354:1425-30.
194. Kroman N, Thorpe SM, Wohlfahrt J, Andersen KW, Mouridsen HT. *Variations in prognostic factors in primary breast cancer throughout the menstrual cycle*. Eur J Surg Oncol **2000**; 26:11-16.
195. Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M. *Factors influencing the effect of age on prognosis in breast cancer: population based study*. Br Med J **2000**; 320:474-9.
196. Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M. *Bør alle yngre mammacancerpatienter tilbydes adjuverende cytotoxisk kemoterapi?* Ugeskr Læg **2000**; 320:474-8.
197. Early Breast Cancer Trialists' Collaborative Group. *Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials*. Lancet **2000**; 355:1757-70.
198. Axelsson CK, Rank F, Blichert-Toft M, Mouridsen HT, Jensen MB on behalf of The Danish Breast Cancer Cooperative Group (DBCG), Rigshospitalet, Copenhagen, Denmark. *Impact of Axillary Dissection on Staging and Regional*

*Control in Breast Tumors ≤10 mm.* Acta Oncol **2000**; 39:283-89.

199. Blichert-Toft M. *Axillary Surgery in Breast Cancer Management. Background, Incidence and Extent of Nodal Spread, Extern of Surgery an Accurate Axillary Staging, Surgical Procedures.* Acta Oncol **2000**; 39:269-275.
200. Johansen J, Overgaard J, Blichert-Toft M, Overgaard M. *Treatment Morbidity Associated with the Management of the Axilla in Breast-Conserving Therapy.* Acta Oncol **2000**; 39:349-54.
201. Lauridsen MC, Tørsleff KR, Husted H, Erichsen C. *Physiotherapy treatment of late symptoms following surgical treatment of breast cancer.* The Breast **2000**; 9:45-51.
202. Rostgaard K, Holst H, Mouridsen HT, Lynge E. *Do clinical databases render population-based cancer registers obsolete? The example of breast cancer in Denmark.* Cancer Causes and Control **2000**; 11:669-74.
203. Ottesen Gyda Lolke, Gravensen Hans Peder, Blichert-Toft Mogens, Christensen Ib Jarle, Andersen Johan A. *Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study.* Breast Cancer Research and Treatment **2000**; 62:197-210
204. Højris I, Andersen J, Overgaard M, Overgaard J. *Late Treatment-Related Morbidity in Breast Cancer Patients Randomized to Postmastectomy Radiotherapy and Systemic Treatment Versus Systemic Treatment Alone.* Acta Oncol **2000**; 39:355-372
- 205.** Kroman N. *Prognostic influence of age and reproductive factors in premenopausal breast cancer patients.* Doctoral Thesis. University of Copenhagen **2001**.
206. Rostgaard K, Mouridsen HT, Væth M, Holst H, Olesen KP, Lynge E. *A Modified Nottingham Prognostic Index for Breast Cancer Patients Diagnosed in Denmark 1978 - 1994.* Acta Oncol **2001**; 40: 838-843.
207. Voogd AC, Nielsen M, Peterse Johannes L, Blichert-Toft M, Bartelink H, Overgaard M, van Tienhoven G, Andersen KW, Sylvester RJ, van Dongen JA, for the Danish Breast Cancer Cooperative Group and the Breast Cancer Cooperative Group of the European Organisation for Research and Treatment of Cancer. *Differences in Risk Factors for Local and Distant Recurrence After Breast-Conserving Therapy or Mastectomy for stage I and II Breast Cancer: Pooled Results of Two Large European Randomized Trials.* J Clin Oncol **2001**; 19: 1688-97.
208. Tange UB, Hirsch FR, Jensen MB, Olsen AH, Blichert-Toft M, Rank FE, Vejborg IMM, Mouridsen HT, soc. Lynge E. *Mammografiscreening i Københavns Kommune. Kliniske konsekvenser efter de første tre screeningsrunder.* Ugeskr Læg **2002**; 164: 1036-40.
209. Tange UB, Hirsch FR, Jensen MB, Olsen AH, Blichert-Toft M, Rank FE, Vejborg IMM, Mouridsen HT, Lynge E. *Mammografiscreening i Københavns Kommune. Populationsresultater fra de første tre screeningsrunder.* Ugeskr Læg **2002**; 164: 1048-52.
210. Blichert-Toft M, Ejlerlsen B, Mouridsen H.T., Overgaard M. *Mammacancer.* Ugeskr Læg **2002**; 164: 3023-6.

211. Johansen J, Overgaard J, Rose C, Engholm S.Aa, Gadeberg C.C., Kjær M, Kamby C, Juul-Christensen J, Blichert-Toft M, Overgaard M, on behalf of the Danish Breast Cancer Cooperative Group (DBCG) and the DBCG Radiotherapy Committee. *Cosmetic Outcome and Breast Morbidity in Breast-Conserving Treatment*. Acta Oncol **2002**; 41: 369-80.
212. Offersen BV, Sørensen FB, Yilmaz M, Knoop A, Overgaard J. *Chalkley Estimates of Angiogenesis in Early Breast Cancer*. Acta Oncol **2002**; 41:695-703.
213. Tange U.B, Jensen M-B, Vejborg I.M.M, Rank F.E, Blichert-Toft M, Mouridsen H.T, Lyng E. *Clinical impact of introduction of mammography screening in a non-screening country*. Scandinavian Journal of Surgery 91: **2002**; 293-303.
214. Kroman N, Melbye M, Mouridsen H.T. *Prognostic influence of age at diagnosis in premenopausal breast cancer patients*. Scandinavian Journal of Surgery 91: **2002**; 305-8.
215. Blichert-Toft M., Smitten K.Von. *Aspects Of Breast Surgery*. Scand.J.of Surg. **2002**; 91:219-21.
216. Blichert-Toft M., Kroman N. *The Specialist Breast Unit and Breast Surgery as a Specialty*. Scand.J.of Surg. **2002**; 91: 227-31
217. Vejborg I., Olsen A.H., Jensen M-B., Rank F., Tange U.B., Lyng E. *Early outcome of mammography screening in Copenhagen 1991-99*. J Med Screen **2002**; 9:115-19.
218. Jensen AR, Overgaard J, Storm HH. *Validity of breast cancer in the Danish Cancer Registry. A study based on clinical records from one county in Denmark*. Eur J Cancer Prevention **2002**; 11:359-364
219. Kroman N., Wohlfahrt J., Mouridsen HT., Melbye M. *Influence of tumor location on breast cancer prognosis*. Int.J.Cancer **2003**; 105: 542-45.
220. Celis JE, Gromov P, Gromova I, Moreira JMA, Cabezon T, Ambartsumian N, Grigorian M, Lukanidin E, Straten PT, Guldborg P, Bartkova J, Bartek J, Lukas J, Lukas C, Lykkesfeldt A, Jäättelä M, Roepstorff P, Bolund L, Ørntoft T, Brüner N, Overgaard J, Sandelin K, Blichert-Toft M, Mouridsen H, Rank FE. *Molecular and cellular Proteomics*. **2003**; 2:369-77.
221. Veronesi U., Cascinelli NML., Greco M., Saccozzi R., Aguilar M., Marubini e., *Long-term survival was similar after breast-conserving surgery or mastectomy for breast cancer*. Evidence-based Obstetrics and Gynecology **2003**; 5: 48-50.
222. Vejborg I, Friis E, Blichert-Toft M. *Brystkræft kan opdages i tide*. Scandinavian Health News, ISBN 87-7749-391-5, FADL's Forlag, København, Oktober, **2003**.
223. Vejborg I, Friis E, Blichert-toft M. *Brystkræft der opdages i tide kan helbredes*. Scandinavian Health News, ISBN 87-7749-416-4, FADL's Forlag, København, Oktober, **2003**.
224. Jensen AJ, Storm HH, Møller S, Overgaard J. *Validity and Representativity in the Danish Breast Cancer Cooperative Group*. **2003**; Acta Oncol 42:179-185
225. Jensen AJ, Garne JP, Storm HH, Ewertz M, Cold S, Alvegaard T, Overgaard J. *Stage and Survival in Breast Cancer Patients in Screened and Non-screened*

Danish and Swedish Populations. **2003**; Acta Oncologica 42:701-709

226. Jensen AR, Ewertz M, Cold S, Storm HH, Overgaard J. *Time trends and regional differences in registration, stage distribution, surgical management and survival of breast cancer in Denmark.* **2003**; Eur J of Cancer 39:1783-1793
227. Offersen BV, Sørensen FB, Knoop A, Overgaard J. *The prognostic relevance of estimates of proliferative activity in early breast cancer.* **2003**; Histopathology 43:573-582
228. Kroman N, Holtveg H, Wohlfahrt J, Jensen MB, Mouridsen HT, Blichert-Toft M, Melbye M. *Effect of Breast-Conserving Therapy versus Radical Mastectomy on Prognosis for Young Women With Breast Carcinoma.* **2004**; Cancer 100:688-93
229. Olsen KE, Knudsen H, Rasmussen BB, Balslev E, Knoop A, Ejlertsen B, Nielsen KV, Schönau A, Overgaard J. *Amplification of HER2 and TOP2A and Deletion of TOP2A Genes in Breast Cancer Investigated by New FISH Probes.* **2004**; Acta Oncol 43:35-42